SMARCB1 and carcinoma: Apart from the analysis on possible cases of SMARCB1-deficient carcinoma and NUT carcinoma, in this study we did not test for these additional characterizing genetic abnormalities; although we analysed copy number alterations on a genome-wide scale, our method was limited by the fact that characterizing mutations were not evaluated.